Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms.

The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Together with Bio-Rad’s existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end solutions feature industry-leading absolute quantification, high precision, and advanced multiplexing capabilities, combined with streamlined and simplified workflows.

“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, EVP and President of Bio-Rad’s Life Science Group. “The newly introduced platforms complement Bio-Rad's existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”

The QX Continuum™ ddPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-color multiplexing and up to eight discrete thermal profiles per plate.

The QX700™ series consists of three new ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-color multiplexing, capacity to process over 700 samples per day, with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.

BIO-RAD, QX CONTINUUM, QX700, QX600, QX200, DROPLET DIGITAL, and DDPCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad  

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives.